Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth hormone replacement therapy and quality of life/cardiovascular risk in GH-deficient adults
2004-004835-72Phase 4Terminated
- Sponsor
- University of Birmingham
- Start
- Feb 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of somatropin in adult onset growth hormone deficiency (AGHD), sponsored by University of Birmingham. Primary endpoint: Quality of life (QoL-AGHDA). Started Feb 2005; status: terminated.
02
Drugs
somatropin
03
Conditions
adult onset growth hormone deficiency (AGHD)
Beyond the preview
Go deeper on 2004-004835-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004835-72.